Progressive fibrosing interstitial lung disease (PF-ILD) has been redefined as a new clinical syndrome that shares similar genetics, pathophysiology, and natural history to idiopathic pulmonary fibrosis (IPF). IPF is the most common form of idiopathic interstitial pneumonias, which is progressive in nature and is associated with significant mortality. Therapies targeting an inflammatory and/or immune response have not been consistently effective or well tolerated in patients with IPF. The two antifibrotic drugs approved for IPF treatment, nintedanib and pirfenidone, have been shown to reduce lung function decline in PF-ILD. Novel uses of antifibrotic therapy are emerging due to a paucity of evidence-based treatments for multiple ILD subtypes. In this review, we describe the current body of knowledge on antifibrotic therapy and immunomodulators in PF-ILD, drawing from experience in IPF where appropriate.
Keywords: Antifibrotic therapy; Chronic hypersensitivity pneumonitis (cHP); Idiopathic pulmonary fibrosis (IPF); Immunosuppressive therapy; Interstitial lung disease (ILD); Nintedanib; Pirfenidone; Progressive fibrosing interstitial lung disease (PF-ILD); Unclassifiable interstitial lung disease (uILD).